Captopril (ACE inhibitor)

Estimated longevity benefit: +1.0 years. Evidence score: 68/100.

Overview

Captopril is an ACE inhibitor that relaxes blood vessels by blocking the renin-angiotensin system, thereby reducing cardiovascular workload and systemic inflammation. Its unique ability to extend both median and maximum lifespan in animal models suggests that vascular preservation is a primary target for slowing systemic aging.

Evidence assessment

Captopril is a first-generation ACE (angiotensin-converting enzyme) inhibitor — the drug class that revolutionized hypertension treatment in the 1980s. It blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, lowering blood pressure, and decreasing the production of aldosterone. Its appearance in the ITP longevity rankings surprised most aging researchers. The primary mechanism for its longevity effect is thought to be the systemic reduction of angiotensin II, a potent pro-oxidant and pro-inflammatory signaling molecule that drives vascular stiffness and organ fibrosis. By dampening this 'vascular aging' axis, captopril protects the integrity of the microvasculature and reduces the cumulative burden of chronic inflammation (inflammaging) throughout the body.

The ITP Finding: The NIA Interventions Testing Program (2022 cohort, published in *Aging Cell*) tested captopril in UM-HET3 genetically heterogeneous mice: - +14% median lifespan increase in males — a clinically meaningful effect - +5% median lifespan in females — smaller but statistically significant - +7–8% maximum lifespan extension in both sexes — critically, even the longest-lived animals benefited - Captopril is one of the few ITP compounds to extend both median AND maximum lifespan in both sexes

This was tested in the same 2022 cohort alongside the rapamycin + acarbose combination, providing direct comparison data.

Why ACE Inhibitors Might Extend Lifespan: Before the ITP result, ACE inhibitors were not considered longevity candidates. The finding points to several mechanisms that may connect the renin-angiotensin system (RAS) to biological aging:

1. Vascular aging: Chronic angiotensin II signaling accelerates vascular smooth muscle proliferation, endothelial dysfunction, and arterial stiffness — all hallmarks of aging. ACE inhibition directly counteracts this. 2. Inflammatory axis: Angiotensin II activates NF-κB signaling, a master regulator of inflammatory gene expression. Captopril reduces this chronic inflammatory stimulus. 3. Mitochondrial effects: ACE2 (the counter-regulatory enzyme) and RAS balance have been linked to mitochondrial function. Captopril may shift this balance toward more efficient mitochondrial metabolism. 4. Kidney protection: The kidneys are major targets of age-related decline. ACE inhibitor protection of renal filtration may translate to broader healthspan benefits. 5. Bradykinin accumulation: ACE inhibitors prevent bradykinin degradation, increasing its tissue concentration. Bradykinin activates nitric oxide signaling pathways associated with vascular health and cardioprotection.

Human Context: ACE inhibitors are among the most prescribed drugs worldwide. Decades of epidemiological data from hypertensive populations show reduced cardiovascular events and mortality in treated patients — consistent with (though not proof of) the ITP longevity finding. The question is whether normotensive individuals would benefit from the same mechanism, a question no human trial has yet addressed for longevity.

Important Sex Difference: The male benefit (+14%) is substantially larger than the female benefit (+5%). This is consistent with the ITP's overall finding that most longevity compounds preferentially extend male lifespan, though captopril is unusual in showing any significant female effect. The biological mechanism appears to involve dampening the pro-inflammatory and pro-fibrotic effects of angiotensin II throughout the body. Evidence is robust in animal models for lifespan extension, particularly in males, while human evidence is currently limited to its well-established benefits in treating cardiovascular disease. A key nuance is that while other ACE inhibitors like lisinopril are more commonly prescribed due to their longer half-life, the ITP specifically validated captopril, leaving open the question of whether its benefits are a class effect or specific to its chemical structure.

Implementation protocol

Critical Warning: Captopril is not a supplement — it is a prescription pharmaceutical that lowers blood pressure through a physiologically potent mechanism. In normotensive individuals, this mechanism can cause symptomatic hypotension (dizziness, fainting) at standard doses, and in individuals with specific anatomical or medical conditions it can cause acute kidney injury or life-threatening airway swelling. - Captopril is FDA-approved for hypertension, heart failure, and kidney disease — NOT for longevity - Requires physician supervision and baseline blood pressure, kidney function (creatinine, eGFR), and potassium testing - Contraindicated in: pregnancy (teratogenic — Category D/X), bilateral renal artery stenosis, history of ACE inhibitor-induced angioedema, concurrent use with aliskiren in diabetics - Not appropriate for normotensive individuals without physician guidance — can cause symptomatic hypotension

Standard Hypertension Dosing (as approved): Captopril's short half-life is a meaningful practical disadvantage — unlike once-daily ACE inhibitors, it requires dosing two to three times per day to maintain consistent angiotensin II suppression throughout the 24-hour cycle. Adherence to divided dosing schedules is substantially lower in real-world practice than in clinical trials. - Captopril: 12.5–50mg two to three times daily - Short half-life (~2 hours) requiring more frequent dosing than newer ACE inhibitors - Most cardiologists now prefer longer-acting ACE inhibitors (lisinopril, ramipril) for once-daily dosing compliance

Longer-Acting Alternatives (if physician-supervised longevity use is pursued): Because the ITP specifically validated captopril rather than the entire ACE inhibitor class, it is unknown whether the longevity benefit is captopril-specific or a class effect. For practical clinical use, a physician may reasonably substitute a longer-acting ACE inhibitor — but the longevity evidence base would technically be extrapolated rather than directly applicable. - Lisinopril 5–20mg once daily - Ramipril 2.5–10mg once daily - Perindopril 4–8mg once daily - These have the same ACE inhibition mechanism as captopril with more convenient dosing

Monitoring: The two primary risks that require ongoing monitoring are blood pressure falling too low and potassium rising too high — both are asymptomatic until they reach a clinically significant threshold, making periodic lab testing essential rather than optional for anyone taking an ACE inhibitor. - Blood pressure: Check regularly; target <120/80 mmHg for longevity context - Renal function (creatinine, eGFR): Baseline, 1 month after starting, then annually - Potassium: ACE inhibitors reduce aldosterone and can cause hyperkalemia — monitor especially if taking potassium-sparing diuretics or high-potassium diet - Cough: The most common side effect (~10–15% of users) — an ACE inhibitor-induced cough from bradykinin accumulation; angiotensin receptor blockers (ARBs) don't cause this

The Longevity Context: The ITP finding for captopril is scientifically compelling because it extends both median and maximum lifespan in both sexes — a combination that suggests a fundamental effect on aging biology rather than a disease-specific benefit. The open question is whether the mechanism (angiotensin II suppression) translates to longevity benefits in the absence of hypertension, and whether the optimal dose in the ITP mouse model corresponds to a pharmacologically equivalent human dose. This intervention is best understood as providing cardiovascular and vascular protection with a plausible longevity mechanism, validated in the ITP but without direct human longevity trial data. For individuals who are hypertensive, ACE inhibitor therapy is standard of care with well-documented mortality benefits. For normotensive individuals seeking purely longevity benefits, the risk-benefit profile requires careful physician evaluation.

Scientific citations

Expert perspectives

Related interventions